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Abstract The creatine kinase (CK) energy transport and
buffering system supports cardiac function at times of high
demand and is impaired in the failing heart. Mice deficient
in muscle- and mitochondrial-CK (M/Mt-CK-/-) have
previously been described, but exhibit an unexpectedly
mild phenotype of compensated left ventricular (LV)
hypertrophy. We hypothesised that heart failure would
develop with age and performed echocardiography and LV
haemodynamics at 1 year. Since all previous studies have
utilised mice with a mixed genetic background, we back-
crossed for [10 generations on to C57BL/6, and repeated
the in vivo investigations. Male M/Mt-CK-/- mice on the
mixed genetic background developed congestive heart
failure as evidenced by significantly elevated end-diastolic
pressure, impaired contractility, LV dilatation, hypertrophy
and pulmonary congestion. Female mice were less severely
affected, only showing trends for these parameters. After
backcrossing, M/Mt-CK-/- mice had LV dysfunction
consisting of impaired isovolumetric pressure changes and
reduced contractile reserve, but did not develop congestive
heart failure. Body weight was lower in knockout mice as a
consequence of reduced total body fat. LV weight was not
significantly elevated in relation to other internal organs
and gene expression of LVH markers was normal, sug-
gesting an absence of hypertrophy. In conclusion, the
consequences of CK deficiency are highly dependent on
genetic modifiers, gender and age. However, the observa-
tion that a primary defect in CK can, under the right con-
ditions, result in heart failure suggests that impaired CK
activity in the failing heart could contribute to disease
progression.
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Introduction
Creatine kinase (CK) is the major phosphotransfer system
in the heart linking energy production to energy utilisation.
Mitochondrial-CK (Mt-CK) catalyses the transfer of a
phosphoryl group from ATP to creatine to form phospho-
creatine (PCr), which transports energy within the cell and
acts as a short-term energy buffer, available for rapid
regeneration of ATP at times of suddenly increased
workload. This reverse reaction is catalysed by cytosolic
CK dimers, consisting of muscle- (M-CK) and brain-
(B-CK) isoforms, with the MM-CK isoenzyme by far the
most prevalent [12, 32].
Down-regulation of the CK system is a hallmark of heart
failure regardless of aetiology [29]. For example, total
creatine is reduced by up to 56 % [18] and CK activity by
up to 48 % [33], and low PCr/ATP ratio is a predictor of
mortality in patients with dilated cardiomyopathy [20],
contributing to the hypothesis that the failing heart is
energy starved [19]. Understanding how such changes
impact on pathophysiology may inform new therapeutic
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approaches, and in support of this, over-expression of
M-CK has recently been shown to protect mice from heart
failure due to pressure overload [11], suggesting CK
changes are not simply an epiphenomenon.
One approach is to study mice with genetic deletion of
key components of the CK system and then determine the
effect on cardiac phenotype in vivo. At the simplest level,
overt dysfunction would indicate potential for a causative
role in the progression to heart failure, but in practice,
interpretation of knockout models is often obfuscated by
physiological redundancy and compensatory adaptations
[2]. CK knockout strains have been created for M-CK,
Mt-CK and the combined double gene deletion [25, 27],
and have proven to be no exception. Loss of M-CK
(*50 % of total CK activity) results in a very mild
phenotype with no overt left ventricular hypertrophy
(LVH) or dysfunction apparent [16, 28, 30]. The double
KO (M/Mt-CK-/-) has a more robust cardiac phenotype,
which is broadly similar to the single Mt-CK-/-, sug-
gesting that loss of Mt-CK rather than up to 98 % loss of
total creatine kinase activity is the driving force [16, 22,
24]. Compensated LVH has been observed in most studies
[13, 16, 17] (although not in all [22, 24]), and likewise
functional defects have not always been evident [22] or
relate only to impaired contractile reserve [7]. Even at
41 weeks of age, there were no differences in MRI
parameters of global function [16], but only subtle
changes in perfusion and ejection times [17]; remarkably,
these mice could survive experimental myocardial
infarction [16].
However, a number of question marks remain con-
cerning the in vivo cardiac phenotype of the M/Mt-CK-/-
mice. Firstly, it is not known whether LVH will eventually
progress to heart failure if studied beyond 41 weeks of age.
Secondly, LV haemodynamic measurements have never
been obtained in vivo, but only at much lower workloads in
Langendorff preparations. Thirdly, all studies to date have
used mice on a mixed C57BL/6 and 129Sv genetic back-
ground. We have previously shown this to be critically
important in Mt-CK-/- mice, where backcrossing to a pure
BL/6 background resulted in loss of the LVH phenotype
[15]. In the current study we address all of these points. We
demonstrate for the first time that M/Mt-CK-/- mice on
the standard mixed background eventually develop con-
gestive heart failure by 1 year of age. We then characterise
a backcrossed strain of M/Mt-CK-/- on a pure BL/6
background and show this to have defects in isovolumetric
contraction/relaxation and reduced body fat, but to no
longer develop LVH or congestive heart failure. Our
findings show for the first time that a chronic primary
defect in creatine kinase ultimately results in congestive
heart failure, but that severity of dysfunction is influenced
by sex and genetic modifiers.
Methods
Mouse colonies
Creatine kinase double knockout mice (i.e. deficient in both
M-CK and mitochondrial-CK isoenzymes) were imported
from a colony at the University of Wu¨rzburg, which in turn
originated from the laboratory of Prof Wieringa (Univer-
sity of Nijmegen, The Netherlands) [25, 27]. These repre-
sent the standard strain reported in the literature, which are
on a non-fixed mixed C57BL/6 and 129Sv genetic back-
ground and are therefore denoted M/Mt-CK-/-(129/Bl6) in
this manuscript. These mice were used for breeding fol-
lowed by initial echocardiography and haemodynamic
studies reported in Fig. 1, with stock C57BL/6 mice used
as control.
Female heterozygotes were backcrossed in our labora-
tory for ten generations with male C57BL/6J mice obtained
from Harlan UK to produce M-CK-/- and M/Mt-CK-/-
mice on a pure genetic background. These mice were
produced by heterozygous mating, so that littermates could
be used as the appropriate wild-type controls (WT). All
investigations were performed when mice were approxi-
mately 1-year-old. Mice were kept under specific patho-
gen-free conditions in individually ventilated cages with
12-h light–dark cycle, controlled temperature (20–22 C),
and fed standard chow and water ad libitum. This inves-
tigation conforms with UK Home Office Guidance on the
Operation of the Animals (Scientific Procedures) Act,
1986.
Echocardiography
Mice were anaesthetised with 4 % isoflurane in medical
oxygen and maintained on a nose-cone at 1–1.5 %. They
were placed supine on a homoeothermic mat, chest fur
shaved and parasternal short and long-axis images
obtained. M/Mt-CK-/-(129/Bl6) mice were imaged with an
Agilent Sonos 5500 equipped with a 7/15 MHz linear-array
transducer, while all subsequent imaging was obtained
under identical conditions using a Visualsonics Vevo 2100
with 22–55 MHz transducer.
Left ventricular haemodynamics
Approximately 1 week after echocardiography, mice were
anaesthetised with 4 % isoflurane in medical oxygen and
maintained on a nose-cone at 1–1.5 % on a homoeothermic
mat. The left ventricle was cannulated via the right carotid
artery using a 1.4-F Millar Mikro-Tip cannula (SPR-839,
Millar Instruments, Houston, Texas). The right jugular vein
was cannulated with stretched polyethylene tubing for
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infusion of dobutamine (16 ng/g body weight/min) to test
contractile reserve. Measurements were obtained after
15 min of equilibration via a Powerlab 4SP data acquisi-
tion system (ADInstruments, UK). At the end of the
experiment, the heart and other organs were excised,
washed in heparinised saline, blotted and weighed. Left
ventricular samples were snap frozen in liquid nitrogen and
stored at -80 C.
Body composition
Body composition analysis was carried out by non-invasive
magnetic resonance relaxometry in conscious restrained
mice using an EchoMRI-100 system (Active Field
Resources, Houston, Texas). Accumulation factor was for
extra-high precision (39) resulting in a scan time of
approximately 2.5 min.
Biochemical and molecular measurements
Total creatine and total CK, CK isoenzyme and citrate
synthase activities were measured from LV homogenates
as previously described [21]. The activity of total adenylate
kinase (AK) was quantified spectrophotometrically as
described in [1]. Total RNA was extracted from LV tissue
and gene expression of LVH markers quantified using real-
time RT-PCR as previously described [15].
Data analysis and statistics
All data were analysed blind to genotype by a single
experienced operator. Data are expressed as mean ±
standard deviation throughout. Comparison between two
groups was by student’s t test, and between three groups





















































































AFig. 1 At 1-year of age, M/Mt-
CK-/-(129/Bl6) mice on a mixed
genetic background (dKO)
develop left ventricular (LV)
hypertrophy and dysfunction.
LV hypertrophy is significant
regardless of whether C57BL/6
or 129SV is used as control
strain, and occurs in both males
and females (Panel a). Panels
b–e are from males only
(n = 5–7, C57BL/6; n = 6–9,
dKO) and indicate significant
LV dilatation in KO mice
measured by echocardiography
(b); impaired LV contractility
(c) and elevated end-diastolic
pressure (d) by in vivo
haemodynamics; and
pulmonary congestion in dKO
mice at post-mortem (e). Values
are mean ± SD
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Bonferroni’s correction for multiple comparisons. Differ-
ences were considered significant when P \ 0.05.
Results
In vivo cardiac phenotype of standard mixed
background CK double knockout mouse
All previously published studies have reported on M/Mt-
CK-/-(129/Bl6) mice with a mixed C57BL/6 and 129Sv
genetic background. When these are maintained by
KO 9 KO breeding, there is no appropriate littermate
control, and standard C57BL/6 mice have historically been
used for this purpose. However, there are reported differ-
ences between C57BL/6 and 129Sv strains for blood
pressure and LV mass [8], so we sought to recapitulate the
finding of LV hypertrophy in M/Mt-CK-/-(129/Bl6) mice
under our own standard laboratory conditions and to
determine whether choice of control had any influence on
the results obtained. Furthermore, we performed in vivo
LV haemodynamic measurements, which have never pre-
viously been reported for M/Mt-CK-/-(129/Bl6) mice.
At 1? years of age (mean 58 weeks), male M/Mt-
CK-/-(129/Bl6) mice had significantly higher LV weight
despite lower body weight and regardless of whether
C57BL/6 (?27 %; P \ 0.001) or 129Sv (?21 %;
P \ 0.01) were used as controls (Fig. 1a). This difference
was still evident after desiccation, suggesting it was not
due to oedema (LV dry weight: 31 ± 2 in C57BL/6 versus
38 ± 6 mg in M/Mt-CK-/-(129/Bl6); P = 0.008). LV
hypertrophy was less pronounced in females, but remained
significant (?17 % versus C57BL/6; P \ 0.05). Echocar-
diography showed that male M/Mt-CK-/-(129/Bl6) mice had
a ?16 % larger cavity cross-sectional area during diastole
indicating significant LV dilatation (Fig. 1b), exhibited
contractile dysfunction (dP/dtmax -31 %), end-diastolic
pressures elevated 4.6-fold and significant pulmonary
congestion compared with control mice (Fig. 1c–e), all
indicative of congestive heart failure (see supplemental
data table 1 for detailed analysis). In female mice, there
were clear trends towards LV dysfunction for all these
parameters, but differences were not statistically significant
(Table 1).
In vivo haemodynamics in 1-year-old CK knockout
mice on a pure C57BL/6 background
All subsequent experiments were obtained in M-CK-/-
and M/Mt-CK-/- mice that were backcrossed in our lab-
oratory with C57BL/6 stock mice for [10 generations.
Comparisons were made with a single wild-type littermate
Table 1 Morphometry and in
vivo cardiac function in 1-year-
old female mice on a mixed
genetic background
Values are mean ± standard
deviation, with P values for
unpaired Student’s t test
Females C57BL/6 M/Mt-CK-/- (129/Bl6) P
Morphometric parameters n = 6 n = 6
Age (weeks) 58 ± 2 56 ± 8 0.57
Body weight (g) 30 ± 4 28 ± 4 0.55
Tibial length (mm) 18.4 ± 0.4 19.0 ± 0.4 0.02
LV weight (mg) 80 ± 6 94 ± 14 0.048
RV weight (mg) 21 ± 2 23 ± 4 0.31
Lung weight (mg) 144 ± 9 159 ± 16 0.07
Liver weight (g) 1.158 ± 0.125 1.182 ± 0.243 0.83
Kidneys (mg) 273 ± 18 368 ± 56 0.003
Haemodynamics n = 6 n = 4
Aortic pressure—systolic (mmHg) 96 ± 5 89 ± 6 0.09
Aortic pressure—diastolic (mmHg) 65 ± 6 58 ± 7 0.13
Aortic pressure—mean (mmHg) 79 ± 4 74 ± 6 0.14
LV end-systolic pressure (mmHg) 98 ± 5 92 ± 7 0.93
LV end-diastolic pressure (mmHg) 4.8 ± 2.9 9.3 ± 4 0.08
dP/dtmax (mmHg/s) 8,684 ± 1,526 6,983 ± 689 0.07
dP/dtmin (mmHg/s) -8,546 ± 1,506 -6,770 ± 1,033 0.08
Heart rate (bpm) 456 ± 35 441 ± 18 0.46
Echocardiography n = 6 n = 6
End-diastolic area (cm2) 0.095 ± 0.012 0.101 ± 0.013 0.42
End-systolic area (cm2) 0.042 ± 0.014 0.041 ± 0.013 0.92
Fractional area change ( %) 57 ± 10 59 ± 11 0.69
Myocardial cross-sectional area (cm2) 0.102 ± 0.017 0.135 ± 0.011 0.002
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control group. Measurement of protein activity in LV
homogenates confirmed loss of target genes, resulting in
residual CK activity of 33 % in M-CK-/- and 0.02 % in
M/Mt-CK-/- mice. There was an increase in BB-CK iso-
enzyme activity of 33 and 100 % for M-CK-/- and M/Mt-
CK-/- hearts, respectively (Table 2), but as this represents
only 2 % of normal total CK activity; however, the sig-
nificance is unclear. There were no compensatory changes
in either adenylate kinase or citrate synthase activities.
Total LV creatine levels were indistinguishable from wild
type (P = 0.46).
There were no significant differences between male and
female mice for haemodynamic parameters when com-
pared within genotypes, and therefore both sexes were
analysed together. However, a detailed breakdown of these
parameters for males and females is provided in supple-
mental data tables 2 and 3, respectively. Total animal
numbers and sex ratios were: WT n = 26 (12 M/14 F),
M-CK-/- n = 31 (14 M/17 F) and M/Mt-CK-/- n = 30
(12 M/18 F). Mean age was 55 weeks in all groups (range
52–59 weeks).
Haemodynamic parameters were indistinguishable
between WT and M-CK-/- mice (Fig. 2). Compared to
wild-type littermates, M/Mt-CK-/- mice had normal LV
end-systolic and end-diastolic pressures (Fig. 2a, b), but
had significantly impaired indices of relaxation (dP/dtmin
31 % lower and tau 31 % longer than WT; Fig. 2c, d) and
contraction (dP/dtmax 23 % lower than WT; Fig. 2g).
Resting heart rate was also significantly lower than WT
(10 %; Fig. 2e). Under conditions of maximal b-adrenergic
stimulation using dobutamine infusion, both maximum
heart rate and dP/dtmax increased in M/Mt-CK
-/- mice, but
remained significantly impaired compared to WT (11 and
24 % lower, respectively; Fig. 2f, h). Thus, the relative
differences in absolute values were maintained, but all
groups showed similar contractile reserve as a percentage
of resting baseline values, i.e. increasing dP/dtmax from
baseline by 27 % (Fig. 2i).
The lower heart rate in M/Mt-CK-/- mice may account
for some (or all) of the difference observed in contractility,
i.e. by occupying different positions on the force–fre-
quency response curve. To investigate this further, dP/
dtmax was correlated with heart rate (Fig. 2j) for both
genotypes: WT Pearson r = 0.61, P = 0.001; M/Mt-
CK-/- Pearson r = 0.84, P \ 0.0001. A runs test indicated
that neither relationship deviated significantly from line-
arity; therefore, linear regression analysis was used to
compare WT with M/Mt-CK-/-. Equation of line for WT
was y = 21.3x – 1,562 and for M/Mt-CK-/- y = 18.3x -
1,273. There was no difference in the slopes (P = 0.58),
but the difference in elevation was highly significant
(P = 0.0004), indicating that WT and M/Mt-CK-/- hearts
do not share the same relationship for dP/dtmax versus heart
rate, but instead run in parallel (i.e. for any given heart rate,
dP/dtmax is lower in M/Mt-CK
-/- hearts).
Echocardiographic examination of M/Mt-CK-/- mice
on the pure genetic background did not reveal any differ-
ence in cardiac volumes or in ejection fraction and cardiac
output (Table 3). Pulmonary artery acceleration and ejec-
tion times were not different suggesting normal RV func-
tion and absence of pulmonary congestion. Transmitral
Doppler was also indistinguishable from wild-type litter-
mates suggesting that LV compliance was unaltered
(Table 3).
Absence of LV hypertrophy on a pure
C57BL/6 background
Postmortem LV weight was not elevated in either
M-CK-/- or M/Mt-CK-/- mice, but body weight was
37 % lower in M/Mt-CK-/- mice, resulting in a high LV/
body weight ratio (Fig. 3a–c). However, LV weight was in
proportion to tibial length and to other major organs such
as liver, kidneys, lungs and total heart weight (Fig. 3d–h).
The same pattern was observed in both males and females
when analysed separately (see supplemental data tables 2
and 3). An absence of LVH was confirmed on a molecular
level by quantitative real-time RT-PCR to measure mRNA
expression of common hypertrophy markers, which were
not up-regulated (Fig. 4). Surprisingly, a-skeletal actin was
elevated in M-CK-/- compared to WT littermate controls;
however, such a change in isolation does not suggest
hypertrophy.
Table 2 Enzyme activities in left ventricular tissue from M-CK-/-











Total CK 5.7 ± 0.8 1.9 ± 0.3 0.12 ± 0.02#
Mt-CK 2.3 ± 0.4 1.8 ± 0.3 0
MM-CK 3.1 ± 0.4 0 0
MB-CK 0.18 ± 0.06 0 0




2.4 ± 0.5 (12) 2.4 ± 0.1 (5) 2.2 ± 0.8 (9)
Citrate
synthase
0.88 ± 0.18 (12) 0.86 ± 0.12 (12) 0.77 ± 0.20 (12)
Mean ± standard deviation
Number of samples is indicated in the headings except where inclu-
ded in parenthesis
* Denotes P \ 0.05,  P \ 0.001 and  P \ 0.0001 compared to wild
type. # Denotes P \ 0.001 for M-CK-/- versus M/Mt-CK-/-
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Fig. 2 Left ventricular in vivo
haemodynamics at 1 year of age
in wild-type (n = 26),
M-CK-/- (n = 31) and M/Mt-
CK-/- (n = 30) mice on a pure
C57BL/6 genetic background.
a, b There were no significant
differences in LV end-systolic
(LVSP) and end-diastolic
pressure (LVEDP),
respectively; c, d diastolic
function was impaired in M/Mt-
CK-/- hearts for both maximal
rate of pressure drop (dP/dtmin)
and isovolumetric constant of
relaxation (tau). e, f Heart rate
was significantly lower in
M/Mt-CK-/- hearts, both at
baseline and under maximal
b-adrenergic stimulation
(16 ng/g Bwt/min dobutamine).
(g, h) Likewise, contractility
was impaired as measured by
maximal rate of pressure
development (dP/dtmax) at
baseline and with dobutamine
infusion, but not when measured
as percentage change from
baseline values (i). j There was
a positive correlation between
contractility (dP/dtmax) and
heart rate for both WT and
M/Mt-CK-/- mice (r = 0.61,
P = 0.001 and r = 0.84,
P \ 0.0001 respectively).
Linear regression analysis
indicated no difference between
slopes, but significantly
different intercepts
(P = 0.0004), suggesting that
impaired contractility in M/Mt-
CK-/- mice was not secondary





P \ 0.05, **P \ 0.01 and
***P \ 0.001
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Body composition
Differences in body weight were investigated further by
magnetic resonance relaxometry in WT and M/Mt-CK-/-
mice. As suggested by organ weight analysis, differences in
body weights were driven by altered body composition and
in particular by drastically reduced fat in M/Mt-CK-/-
mice. This was accompanied to a lesser extent by lower
total body water and lean weight (Fig. 5a–e). These highly
significant differences were observed in both male and
female mice (supplemental data table 4). There was a lin-
ear relationship between percentage body fat and body
water for both WT and M/Mt-CK-/- mice that was
indistinguishable, suggesting that they are at different ends
of the same continuum (Fig. 5e).
Discussion
In this study, we show that the in vivo phenotype is highly
dependent on genetic background, gender and age, and that
there are major changes to body weight and composition.
Previous reports of CK knockout mice have utilised strains
on a mixed, non-fixed, genetic background, have seldom
reported male-to-female ratios, and have not looked
beyond 41 weeks of age. These variables are likely to
explain why reports in this strain, for example relating to
LV hypertrophy, have at times been contradictory.
Male M/Mt-CK-/- on a mixed genetic background
develop heart failure
M/Mt-CK-/-(129/Bl6) mice (i.e. on a standard mixed back-
ground) have previously been studied up to 41 weeks of
age, at which point they had extensive LVH, mild dilata-
tion and normal ejection fraction by MRI [16, 17]. We have
Table 3 Echocardiography at 1 year of age in male M/Mt-CK-/-




n = 6 (4 M/2 F) n = 9 (6 M/3 F)
Heart rate (bpm) 493 ± 39 493 ± 46 0.98
End-diastolic volume
(ll)
62 ± 14 61 ± 15 0.94
End-systolic volume
(ll)
29 ± 8 27 ± 11 0.80
Stroke volume (ll) 33 ± 10 34 ± 8 0.87
Cardiac output (ml/min) 16.2 ± 4.3 16.7 ± 4.6 0.83
Ejection fraction (%) 53 ± 7 56 ± 9 0.58





21 ± 3 21 ± 4 0.75
PET—ejection time
(ms)
60 ± 8 57 ± 7 0.45
PAT/PET 0.36 ± 0.04 0.36 ± 0.04 0.87
Transmitral Doppler
E wave (mm/s) 543 ± 168 660 ± 201 0.32
A wave (mm/s) 358 ± 143 381 ± 157 0.80
E/A 1.6 ± 0.5 1.8 ± 0.3 0.41
Values are mean ± standard deviation, with P values for unpaired
Student’s t test
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Fig. 3 Analysis of postmortem left ventricular (LV) weight at 1 year
of age in wild-type (n = 26), M-CK-/- (n = 31) and M/Mt-CK-/-
(n = 30) mice on a pure C57BL/6 genetic background. (a) Body
weight is significantly lower in M/Mt-CK-/- mice, but with normal
absolute LV weight (b), this results in a higher LV/body weight ratio
(c). However, this difference is driven by changes in body compo-
sition affecting body weight, since LV weight is not elevated when
compared with tibial length (d), or other major organs such as liver
(e), kidneys (f) and lung (g) and as percentage of whole heart weight
(h). Mean ± SD; * denotes P \ 0.05, **P \ 0.01 and ***P \ 0.001

















































































Fig. 4 Relative gene
expression of hypertrophy
markers in left ventricular tissue
from 1-year-old wild-type,
M-CK-/- and M/Mt-CK-/-
mice on a pure C57BL/6 genetic
background (n = 3
male ? n = 3 female of each
genotype). ANP atrial
natriuretic peptide, BNP brain
natriuretic peptide, b-MHC
b-myosin heavy chain.



















































































M/Mt-CK-/- r 2=0.91, y=-1.02x+77




Fig. 5 Body composition
analysis by magnetic resonance
relaxometry at 1-year of age in
wild-type (n = 11) and M/Mt-
CK-/- (n = 14) mice on a pure
C57BL/6 genetic background.
Body weight (a); total body fat
(b); total body water (c); lean
weight (d). The relationship
between percentage body fat
and percentage body water was
preserved in M/Mt-CK-/- mice
with a linear relationship
indistinguishable from wild
type. Mean ± SD; ** denotes
P \ 0.01 and ***P \ 0.001
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now demonstrated that at 1 year of age this compensated
hypertrophy eventually progresses to heart failure, but only
in males, with females much less severely affected. Since
previous studies have used stock C57BL/6 as a control for
Mt-CK-/-(129/Bl6) mice, we also demonstrated that the
choice of control, whether C57BL/6 or 129Sv, does not
affect the extent of LVH observed. Previous studies mea-
sured cardiac function using MRI, and in our experience it
is not unusual to find minimal differences in global imag-
ing parameters, yet still observe large differences in LV
pressures. For example, we have previously shown that
creatine-deficient mice have normal ejection fraction, but
impaired pressure-generating capacity [26]. This should
not be surprising, as these parameters report very different
phases in the cardiac cycle.
Creatine kinase-deficient mice survive for a long time
with only mild dysfunction, so obviously CK activity is not
obligatory for cardiac function, but the finding that male
M/Mt-CK-/-(129/Bl6) mice eventually develop heart failure
suggests that loss of CK places a chronic strain on the heart
and that gender modulates the effects of CK depletion.
Multiple changes have been described in the ageing heart
that impact on its ability to tolerate stress [5], and this may
result in the gradual unmasking of the functional phenotype
over time. A wide range of potentially compensatory
adaptations have been described in M/Mt-CK-/-(129/Bl6)
mice to explain the mild early phenotype, for example,
closer juxtaposition of mitochondria with myofilaments,
thereby reducing diffusion distance [13], coupling of gly-
colysis with the SERCA pump [4] and increased mito-
chondrial capacity with flux through alternative
phosphotransfer pathways [9]. It may be that these changes
are inefficient or energy costly and therefore cannot be
maintained as a compensatory mechanism in the long term.
This also suggests that reduced CK activity, as occurs in the
failing heart [14] and in viral myocarditis [10], may indeed
contribute to disease progression. Although CK dysfunction
is not as severe as in the double knockout, the effect is likely
to be amplified when overlaid on existing organic disease
and in combination with gross changes in cellular processes,
inflammation and neuro-endocrine signalling.
M/Mt-CK-/- on a pure genetic background have
a milder cardiac phenotype
We have previously shown that genetic background has a
major effect on the phenotype of Mt-CK-/- mice [15]. We
therefore backcrossed M-CK-/- and M/Mt-CK-/- lines
until they were congenic with C57BL/6 mice (theoretically
99.9 % identical). This did not alter the phenotype in
M-CK-/- mice, which remained mild to non-existent even
when studied at 1-year of age. However, M/Mt-CK-/-
mice had a less severe phenotype compared to M/Mt-
CK-/-(129/Bl6); most notably, they had normal end-diastolic
pressure and an absence of LVH and pulmonary conges-
tion. It is likely that this disparity purely reflects genetic
differences rather than environmental or experimental
influences such as diet or pathogen status, since M/Mt-
CK-/-(129/Bl6) obtained from Wu¨rzburg but kept in our
laboratory developed LV hypertrophy as expected. Clearly,
the backcrossed mice are no longer in heart failure, which
suggests the existence of powerful genetic modifiers in the
C57BL/6 background to account for this. Future identifi-
cation of these modifiers may suggest therapeutic targets
for heart failure.
A lack of LVH is in agreement with our previous find-
ings in Mt-CK-/- mice, which had up-regulation of M-CK
and citrate synthase as potential compensatory pathways
[15]. We predicted that backcrossed M/Mt-CK-/- mice
would therefore have a more pronounced phenotype, since
they have no M-CK with which to compensate with. This
does appear to be the case since backcrossed M/Mt-CK-/-
had impaired indices of isovolumetric function that were
not observed in Mt-CK-/- mice at the same age. A
potential compensatory role for increased mitochondrial
capacity (as suggested by elevated citrate synthase) was
observed in our backcrossed Mt-CK-/- mice [15] and also
recently in the M/Mt-CK-/-(129/Bl6) strain [9]. However,
we did not observe an increase in citrate synthase activity
in our backcrossed M/Mt-CK-/- strain even though they
had a milder phenotype, which argues against a compen-
satory role.
Genetic background and the choice of control
It is increasingly recognised that genetic background can
have a major influence on observed phenotypes in terms of
both normal cardiac function [8, 31] and response to
pathological stress [3], and we have previously shown this
to be true for Mt-CK-/- mice [15]. This underlines the
importance of using appropriate controls in mouse studies.
The optimal control for a double knockout mouse is to use
heterozygous mating to produce double WT littermates for
comparison, and this is the approach we took for the mice
on a pure C57BL/6 background. This would also be opti-
mal for mice on a non-fixed, mixed background, even
though random mixing will mean that wild-type mice are
not genetically identical. However, we chose to use stock
C57BL/6 as controls for the experiments on M/Mt-CK-/-
(129/Bl6) mice, because we wanted to emulate the conditions
used in previous studies to determine whether we could
recapitulate their findings. The limitations of using a poor
control in those studies are therefore shared by our
experiments on M/Mt-CK-/-(129/Bl6) mice.
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Whole body phenotype
An unexpected finding, not previously described in the lit-
erature, was lower body weight observed in M/Mt-CK-/-
mice regardless of genetic background (although not in
female M/Mt-CK-/-(129/Bl6)). Using non-invasive body
composition analysis, we established that this was mainly
driven by reduced body fat in knockout mice. Water content
was also reduced in M/Mt-CK-/- mice; however, water is
linearly related to fat over a wide range of body composi-
tions in the mouse [6], therefore the preservation of the fat-
to-water relationship suggests that this change is secondary
to alterations in fat content. Although less pronounced, this
pattern is very similar to creatine-free (GAMT knockout)
mice [23] and indicates that disruption of the CK system has
profound effects on whole body metabolism.
Conclusions
Mice with chronic deficiency of both muscle- and mito-
chondrial-creatine kinase develop compensated LV hyper-
trophy that eventually progresses to congestive heart failure.
The extent of this phenotype is highly dependent on genetic
background, gender and age. That a primary defect in the
creatine kinase system can, in itself, result in heart failure
lends credence to the hypothesis that impaired CK activity
observed in the failing heart may contribute to disease pro-
gression and is therefore a target for therapeutic intervention.
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